Tofacitinib Global Market Report 2024

Description

“Tofacitinib Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tofacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tofacitinib? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The tofacitinib market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Antirheumatic; Janus Kinase Inhibitor; Immunosuppressant
2) By Strength: 5mg; 10mg; 11mg; 22mg
3) By Route Of Administration: Oral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By Application: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis; Other Applications
Companies Mentioned: Beacon Pharmaceuticals Limited; Pfizer Inc.; Globe Pharmaceuticals Ltd.; Drug International Limited; Dolphin Pharmaceuticals
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Tofacitinib is a medication employed in the treatment of ulcerative colitis and various rheumatic diseases, including rheumatoid arthritis and ankylosing spondylitis. It is specifically used for moderate to severely active ulcerative colitis cases when there is intolerance, inadequate response, or a loss of response to biological therapy or conventional treatments.

The primary drug classes to which tofacitinib belongs include antirheumatic, Janus kinase inhibitor, and immunosuppressant. Antirheumatic denotes any medication utilized for treating rheumatism. Tofacitinib is available in strengths of 5mg, 10mg, 11mg, and 22mg, with administration routes including oral and others. The distribution channels for this medication encompass hospital pharmacies, retail pharmacies, and online pharmacies. Tofacitinib is indicated for conditions such as ulcerative colitis, rheumatoid arthritis, psoriasis, and others.

The tofacitinib market research report is one of a series of new reports from The Business Research Company that provides tofacitinib market statistics, including tofacitinib industry global market size, regional shares, competitors with tofacitinib market share, detailed tofacitinib market segments, market trends, and opportunities, and any further data you may need to thrive in the tofacitinib industry. This tofacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tofacitinib market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.12 billion in 2024 at a compound annual growth rate (CAGR) of 13.0%. The expansion observed in the historical period can be ascribed to factors such as clinical efficacy and trials, regulatory approvals, an increase in the incidence of targeted conditions, physician prescribing patterns, and patient acceptance.

The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth in the forecast period can be linked to factors such as expanded indications, market access initiatives, the competitive landscape, real-world evidence, and patient-centric healthcare. Noteworthy trends expected in the forecast period include a focus on the treatment of pediatric rheumatoid arthritis, exploration of tofacitinib in dermatological conditions, strategic collaborations and partnerships, integration of real-world evidence in treatment guidelines, and a focus on personalized medicine approaches.

The expected rise in the prevalence of rheumatoid arthritis is anticipated to fuel the growth of the tofacitinib market. Rheumatoid arthritis, an autoimmune and inflammatory disorder affecting joints, internal organs, hands, and feet, sees tofacitinib medications targeting Janus kinase enzymes, preventing their activity and mitigating inflammation. For example, data from the National Arthritis Data Workgroup in February 2022 revealed that over 52.5 million adults in the United States, exceeding 22% of the population, had received diagnoses of arthritis or other rheumatic diseases. Predictions indicate that adults aged 18 and above with arthritis could reach 67 million by 2030. Thus, the increasing prevalence of rheumatoid arthritis contributes to the growth of the tofacitinib market.

The growing number of patients grappling with inflammatory bowel disease is poised to propel the tofacitinib market's expansion. Inflammatory Bowel Disease (IBD), encompassing chronic inflammatory conditions such as Crohn's disease and ulcerative colitis, witnesses tofacitinib's pivotal role in managing symptoms by inhibiting Janus kinase (JAK) enzymes and promoting mucosal healing. Statistics from Crohn's and Colitis Canada in June 2023 estimated that over 322,600 Canadians were living with IBD, accounting for about 0.82% of the population. Projections suggest that by 2035, around 470,000 Canadians, or approximately 1.1% of the population, may be living with IBD. This ongoing prevalence of IBD contributes to the escalating growth of the tofacitinib market.

Product innovation stands out as a prominent trend gaining momentum in the tofacitinib market. Leading companies in the tofacitinib market are actively engaged in developing innovative products to maintain their market position. An illustrative example is Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, which announced in December 2021 that the U.S. Food and Drug Administration (FDA) had approved a supplemental New Drug Application (sNDA) for tofacitinib-based medications XELJANZ and XELJANZ XR. XELJANZ marks the first and only Janus kinase (JAK) inhibitor authorized in the United States for treating five immuno-inflammatory diseases. The approval of XELJANZ for ankylosing spondylitis (AS) was based on a Phase 3 multicenter, randomized, double-masked, placebo-controlled study that assessed the safety and efficacy of tofacitinib.

Major companies in the tofacitinib market are placing increased emphasis on introducing topical tofacitinib medications to gain a competitive advantage. Topical tofacitinib refers to a formulation designed for topical application on the skin. A noteworthy instance is Intas Pharmaceuticals, an India-based pharmaceutical company, which launched Tofacitinib Topical (JAKi) in June 2023 for treating mild to moderate atopic dermatitis (AD) in India. This marks the first approval of a JAK inhibitor for AD in India. The successful Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) demonstrated notable safety and efficacy in atopic dermatitis patients. The introduction of TOFATAS is aimed at providing renewed hope to AD patients, addressing an unmet need for approved topical JAK inhibitors in India.

In March 2022, Pfizer Inc. furthered its market position through the acquisition of Arena Pharmaceuticals for $6.7 billion. This strategic move enhances Pfizer Inc.'s portfolio by adding potential drugs for gastroenterology, dermatology, and cardiology, including a potential follow-up to the inflammatory disorder drug Xeljanz (tofacitinib). Arena Pharmaceuticals, a US-based biopharmaceutical company, brings small-molecule medications into Pfizer Inc.'s pipeline, expanding the potential clinical applications across various therapeutic fields.

Major companies operating in the tofacitinib market report are Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals Ltd., Drug International Limited, Dolphin Pharmaceuticals, Lancer Therapeutics, Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Lifesciences Ltd., Esteve Pharmaceuticals SA, Unichem Laboratories, Beijing Mesochem Technology Co. Ltd., Aprazer Healthcare Pvt Ltd., Apino Pharma Co Ltd., Delta Pharma Limited, Mediconlife, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Jubilant Life Sciences, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited

North America was the largest region in the tofacitinib market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the tofacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The tofacitinib market consists of sales of Xeljanz and Xeljanz XR. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12152

1. Executive Summary

2. Tofacitinib Market Characteristics

3. Tofacitinib Market Trends And Strategies

4. Tofacitinib Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Tofacitinib Market Size and Growth

5.1. Global Tofacitinib Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Tofacitinib Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Tofacitinib Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Tofacitinib Market Segmentation

6.1. Global Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Antirheumatic
Janus Kinase Inhibitor
Immunosuppressant
6.2. Global Tofacitinib Market, Segmentation By Strength, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
5mg
10mg
11mg
22mg
6.3. Global Tofacitinib Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Oral
Other Routes Of Administration
6.4. Global Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.5. Global Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Ulcerative Colitis
Rheumatoid Arthritis
Psoriasis
Other Applications

7. Tofacitinib Market Regional And Country Analysis

7.1. Global Tofacitinib Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Tofacitinib Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Tofacitinib Market

8.1. Asia-Pacific Tofacitinib Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Tofacitinib Market

9.1. China Tofacitinib Market Overview
9.2. China Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Tofacitinib Market

10.1. India Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Tofacitinib Market

11.1. Japan Tofacitinib Market Overview
11.2. Japan Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Tofacitinib Market

12.1. Australia Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Tofacitinib Market

13.1. Indonesia Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Tofacitinib Market

14.1. South Korea Tofacitinib Market Overview
14.2. South Korea Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Tofacitinib Market

15.1. Western Europe Tofacitinib Market Overview
15.2. Western Europe Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Tofacitinib Market

16.1. UK Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Tofacitinib Market

17.1. Germany Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Tofacitinib Market

18.1. France Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Tofacitinib Market

19.1. Italy Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Tofacitinib Market

20.1. Spain Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Tofacitinib Market

21.1. Eastern Europe Tofacitinib Market Overview
21.2. Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Tofacitinib Market

22.1. Russia Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Tofacitinib Market

23.1. North America Tofacitinib Market Overview
23.2. North America Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Tofacitinib Market

24.1. USA Tofacitinib Market Overview
24.2. USA Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Tofacitinib Market

25.1. Canada Tofacitinib Market Overview
25.2. Canada Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Tofacitinib Market

26.1. South America Tofacitinib Market Overview
26.2. South America Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Tofacitinib Market

27.1. Brazil Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Tofacitinib Market

28.1. Middle East Tofacitinib Market Overview
28.2. Middle East Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Tofacitinib Market

29.1. Africa Tofacitinib Market Overview
29.2. Africa Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Tofacitinib Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Tofacitinib Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Tofacitinib Market Competitive Landscape And Company Profiles

30.1. Tofacitinib Market Competitive Landscape
30.2. Tofacitinib Market Company Profiles
- 30.2.1. Beacon Pharmaceuticals Limited
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Pfizer Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Globe Pharmaceuticals Ltd.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Drug International Limited
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Dolphin Pharmaceuticals
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Tofacitinib Market Competitive Benchmarking

32. Global Tofacitinib Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Tofacitinib Market

34. Tofacitinib Market Future Outlook and Potential Analysis

34.1 Tofacitinib Market In 2028 - Countries Offering Most New Opportunities
34.2 Tofacitinib Market In 2028 - Segments Offering Most New Opportunities
34.3 Tofacitinib Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer